Header Logo

Connection

SALIM VIRANI to Anticholesteremic Agents

Back to Details
This is a "connection" page, showing publications SALIM VIRANI has written about Anticholesteremic Agents.
SALIM VIRANI
Connection Strength
11.122
Anticholesteremic Agents
  1. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2026 American College of Cardiology Conference. Curr Atheroscler Rep. 2026 May 16; 28(1).
    View in: PubMed
    Score: 0.795
  2. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress. Curr Atheroscler Rep. 2023 12; 25(12):965-978.
    View in: PubMed
    Score: 0.669
  3. The underutilization of preventive cardiovascular measures in patients with cancer: an analysis of the Behavioural Risk Factor Surveillance System, 2011-22. Eur J Prev Cardiol. 2023 09 20; 30(13):1325-1332.
    View in: PubMed
    Score: 0.661
  4. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American College of Cardiology Conference. Curr Atheroscler Rep. 2023 06; 25(6):309-321.
    View in: PubMed
    Score: 0.643
  5. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American Heart Association Scientific Sessions. Curr Atheroscler Rep. 2023 01; 25(1):31-41.
    View in: PubMed
    Score: 0.630
  6. PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance. Vasc Health Risk Manag. 2022; 18:555-566.
    View in: PubMed
    Score: 0.610
  7. Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions. Curr Atheroscler Rep. 2022 01; 24(1):61-72.
    View in: PubMed
    Score: 0.590
  8. Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018?AHA/ACC Cholesterol Guidelines. J Am Coll Cardiol. 2019 08 06; 74(5):712-714.
    View in: PubMed
    Score: 0.497
  9. PCSK9 Inhibitors Prior Authorization. Circ Cardiovasc Qual Outcomes. 2019 08; 12(8):e005910.
    View in: PubMed
    Score: 0.496
  10. The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know. Curr Atheroscler Rep. 2019 04 02; 21(6):20.
    View in: PubMed
    Score: 0.485
  11. Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation. 2019 01 15; 139(3):410-412.
    View in: PubMed
    Score: 0.478
  12. Lipid-Lowering Therapies: Risks in Women and Evidence-Based Options. Tex Heart Inst J. 2018 08; 45(4):238-239.
    View in: PubMed
    Score: 0.463
  13. The 2013 ACC/AHA Cholesterol Management Guideline: Clearing the Confusion from Noncontroversial Components. Tex Heart Inst J. 2016 Aug; 43(4):313-4.
    View in: PubMed
    Score: 0.403
  14. The Role of Ezetimibe in the Treatment of Cardiovascular Disease. Curr Atheroscler Rep. 2016 Feb; 18(2):8.
    View in: PubMed
    Score: 0.390
  15. Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria. Am J Med. 2015 Nov; 128(11):1253-6.
    View in: PubMed
    Score: 0.372
  16. What is new in the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic risk in adults? Tex Heart Inst J. 2014 Jun; 41(3):304-5.
    View in: PubMed
    Score: 0.347
  17. Novel therapies for treating familial hypercholesterolemia. Curr Atheroscler Rep. 2014 Jan; 16(1):382.
    View in: PubMed
    Score: 0.337
  18. Inclisiran as a siRNA Inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); Past, Present, and Future. Am J Cardiovasc Drugs. 2025 May; 25(3):293-306.
    View in: PubMed
    Score: 0.180
  19. Novel therapies to achieve the recommended low-density lipoprotein cholesterol concentration (LDL-C) targets for patients after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2024 02; 167(2):723-730.e4.
    View in: PubMed
    Score: 0.162
  20. A stepwise approach to prescribing novel lipid-lowering medications. J Clin Lipidol. 2022 Nov-Dec; 16(6):822-832.
    View in: PubMed
    Score: 0.155
  21. Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization Between 2015 and 2019. Circ Cardiovasc Qual Outcomes. 2022 12; 15(12):e008861.
    View in: PubMed
    Score: 0.155
  22. Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022 02 09; 28(18):2001-2009.
    View in: PubMed
    Score: 0.148
  23. High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. Mayo Clin Proc. 2021 10; 96(10):2660-2670.
    View in: PubMed
    Score: 0.144
  24. How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol. Eur Heart J. 2021 06 07; 42(22):2154-2169.
    View in: PubMed
    Score: 0.141
  25. Cardiovascular Disease Prevention in Focus: Highlights from the 2019 American Heart Association Scientific Sessions. Curr Atheroscler Rep. 2020 01 11; 22(1):3.
    View in: PubMed
    Score: 0.128
  26. Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). Am J Cardiol. 2020 03 15; 125(6):874-879.
    View in: PubMed
    Score: 0.128
  27. 2018 Cholesterol Guidelines: Key Topics in Primary Prevention. Curr Atheroscler Rep. 2019 03 16; 21(5):17.
    View in: PubMed
    Score: 0.121
  28. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 06 18; 139(25):e1046-e1081.
    View in: PubMed
    Score: 0.118
  29. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 06 18; 139(25):e1082-e1143.
    View in: PubMed
    Score: 0.118
  30. Lipoprotein(a) and cardiovascular disease: current state and future directions for an enigmatic lipoprotein. Front Biosci (Landmark Ed). 2018 01 01; 23(6):1099-1112.
    View in: PubMed
    Score: 0.111
  31. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial. JAMA Cardiol. 2017 12 01; 2(12):1369-1374.
    View in: PubMed
    Score: 0.111
  32. Applicability of the IMPROVE-IT Trial to Current Patients With Acute Coronary Syndrome: An NCDR Research to Practice Project. JAMA Intern Med. 2017 06 01; 177(6):887-889.
    View in: PubMed
    Score: 0.107
  33. Non-high-density lipoprotein cholesterol reporting and goal attainment in primary care. J Clin Lipidol. 2012 Nov-Dec; 6(6):545-52.
    View in: PubMed
    Score: 0.075
  34. Four Cases of Cholesterol Management Informed by the 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol. JAMA Cardiol. 2019 05 01; 4(5):473-477.
    View in: PubMed
    Score: 0.030
  35. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task?Force?on?Clinical Practice Guidelines. J Am Coll Cardiol. 2019 06 25; 73(24):3168-3209.
    View in: PubMed
    Score: 0.030
  36. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task?Force?on?Clinical Practice Guidelines. J Am Coll Cardiol. 2019 06 25; 73(24):e285-e350.
    View in: PubMed
    Score: 0.030
  37. Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project. Am Heart J. 2018 01; 195:151-152.
    View in: PubMed
    Score: 0.027
  38. Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: Practice impact of the new cholesterol guidelines. Am Heart J. 2016 Dec; 182:97-102.
    View in: PubMed
    Score: 0.025
  39. Lipid management: considerations in acute coronary syndrome. Curr Cardiol Rep. 2008 Jul; 10(4):334-41.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.